VERITAS: Harnessing the power of nomenclature in biologic discovery
ABSTRACTWe are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision. Therefore, considering even a dozen such formats, in co...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2207232 |
| _version_ | 1827240483207774208 |
|---|---|
| author | Riti Biswas Ed Belouski Kevin Graham Michelle Hortter Marissa Mock Christine E. Tinberg Alan J. Russell |
| author_facet | Riti Biswas Ed Belouski Kevin Graham Michelle Hortter Marissa Mock Christine E. Tinberg Alan J. Russell |
| author_sort | Riti Biswas |
| collection | DOAJ |
| description | ABSTRACTWe are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision. Therefore, considering even a dozen such formats, in combination with hundreds of possible targets, can create confusion and increase the complexity of drug discovery. To address this challenge, we introduce Verified Taxonomy for Antibodies (VERITAS). This classification and nomenclature scheme is extensible to multispecific therapeutic formats and beyond. VERITAS names are easy to understand while drawing direct connections to the structure of a given format, with or without specific target information, making these names useful to adopt in scientific discourse and as inputs to machine learning algorithms for drug development. |
| first_indexed | 2024-03-08T14:24:22Z |
| format | Article |
| id | doaj.art-a742f5fea5fa4f1dba7e11771a364ca2 |
| institution | Directory Open Access Journal |
| issn | 1942-0862 1942-0870 |
| language | English |
| last_indexed | 2025-03-21T21:25:18Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj.art-a742f5fea5fa4f1dba7e11771a364ca22024-05-28T15:55:47ZengTaylor & Francis GroupmAbs1942-08621942-08702023-12-0115110.1080/19420862.2023.2207232VERITAS: Harnessing the power of nomenclature in biologic discoveryRiti Biswas0Ed Belouski1Kevin Graham2Michelle Hortter3Marissa Mock4Christine E. Tinberg5Alan J. Russell6Biologic Therapeutic Discovery, Amgen Research, South San Francisco, CA, USABiologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USABiologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USABiologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USABiologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USABiologic Therapeutic Discovery, Amgen Research, South San Francisco, CA, USABiologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USAABSTRACTWe are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision. Therefore, considering even a dozen such formats, in combination with hundreds of possible targets, can create confusion and increase the complexity of drug discovery. To address this challenge, we introduce Verified Taxonomy for Antibodies (VERITAS). This classification and nomenclature scheme is extensible to multispecific therapeutic formats and beyond. VERITAS names are easy to understand while drawing direct connections to the structure of a given format, with or without specific target information, making these names useful to adopt in scientific discourse and as inputs to machine learning algorithms for drug development.https://www.tandfonline.com/doi/10.1080/19420862.2023.2207232Antibody engineeringantibody formatsantibody nomenclaturebispecific antibodiesmultispecific antibodiestherapeutic antibodies |
| spellingShingle | Riti Biswas Ed Belouski Kevin Graham Michelle Hortter Marissa Mock Christine E. Tinberg Alan J. Russell VERITAS: Harnessing the power of nomenclature in biologic discovery mAbs Antibody engineering antibody formats antibody nomenclature bispecific antibodies multispecific antibodies therapeutic antibodies |
| title | VERITAS: Harnessing the power of nomenclature in biologic discovery |
| title_full | VERITAS: Harnessing the power of nomenclature in biologic discovery |
| title_fullStr | VERITAS: Harnessing the power of nomenclature in biologic discovery |
| title_full_unstemmed | VERITAS: Harnessing the power of nomenclature in biologic discovery |
| title_short | VERITAS: Harnessing the power of nomenclature in biologic discovery |
| title_sort | veritas harnessing the power of nomenclature in biologic discovery |
| topic | Antibody engineering antibody formats antibody nomenclature bispecific antibodies multispecific antibodies therapeutic antibodies |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2023.2207232 |
| work_keys_str_mv | AT ritibiswas veritasharnessingthepowerofnomenclatureinbiologicdiscovery AT edbelouski veritasharnessingthepowerofnomenclatureinbiologicdiscovery AT kevingraham veritasharnessingthepowerofnomenclatureinbiologicdiscovery AT michellehortter veritasharnessingthepowerofnomenclatureinbiologicdiscovery AT marissamock veritasharnessingthepowerofnomenclatureinbiologicdiscovery AT christineetinberg veritasharnessingthepowerofnomenclatureinbiologicdiscovery AT alanjrussell veritasharnessingthepowerofnomenclatureinbiologicdiscovery |